Recent 8-K filings for ABSI

• May 7, 2026, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 8.01item 9.01 ◈ Earnings Releases

  Absci completes all SAD cohorts of ABS-201, initiates MAD; Q1 net loss $29.6M

  Successfully dosed all four SAD cohorts of ABS-201 Phase 1/2a; well-tolerated with favorable safety.

• March 24, 2026, 7:59 PM ET other material materiality 0.70 neutral item 2.02item 8.01item 9.01

  Absci reports Q4 net loss $29.6M, advances ABS-201 trial, appoints new CMO

  Dosed first three cohorts in SAD portion of Phase 1/2a HEADLINE trial for ABS-201; well-tolerated with favorable emerging safety.

• March 6, 2026, 6:59 PM ET leadership materiality 0.65 neutral item 1.01item 5.02item 7.01item 9.01

  Absci appoints Ransi Somaratne as CMO; Chief Innovation Officer Andreas Busch to retire

  Ransi Somaratne, formerly SVP Clinical Development at Vertex, appointed CMO effective March 3, 2026.

• November 12, 2025, 6:59 PM ET earnings materiality 0.80 neutral item 2.02item 8.01item 9.01

  Absci Reports Q3 2025 Results, Advances ABS-201 and ABS-101 Programs

  Reported interim Phase 1 data for ABS-101 (anti-TL1A) showing extended half-life with no serious adverse events.

• August 12, 2025, 7:59 PM ET earnings materiality 0.75 neutral item 9.01item 2.02item 8.01

  Absci Q2 2025 net loss $30.6M; raises $64M in July; Almirall collaboration expands

  Q2 2025 revenue $0.6M (down from $1.3M YoY); net loss $30.6M vs $24.8M prior year.

• August 12, 2025, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 8.01item 9.01

  Absci Q2 net loss $30.6M; raises $64M in July extending runway to H1 2028; Almirall collaboration expands

  Net loss $30.6M in Q2 2025 (vs $24.8M in Q2 2024); revenue $0.6M (vs $1.3M).

• July 25, 2025, 7:59 PM ET other material materiality 0.70 neutral item 1.01item 8.01item 9.01

  Absci prices $50M public offering of 16.67M shares at $3.00 per share

  Offering of 16,670,000 shares at $3.00 per share; gross proceeds ~$50M.

• May 13, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 8.01item 9.01

  Absci starts Phase 1 dosing for ABS-101; Q1 net loss $26.3M, cash into H1 2027

  Initiated dosing in first-in-human Phase 1 study of ABS-101 (anti-TL1A); interim data expected H2 2025.

• March 18, 2025, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 8.01item 9.01

  Absci Q4 revenue $0.7M, net loss $29M; pipeline advances and AMD collaboration

  Q4 revenue $0.7M (vs $0.3M YoY); net loss $29.0M vs $23.5M.

• November 12, 2024, 6:59 PM ET earnings materiality 0.70 neutral item 2.02item 8.01item 9.01

  Absci Q3 revenue $1.7M, net loss $27.4M; achieves AstraZeneca milestone, lowers 2024 cash burn guidance to ~$75M

  Revenue $1.7M (up from $0.7M YoY); net loss $27.4M vs $22.0M; cash $127.1M at Sept 30, 2024.

• September 4, 2024, 7:59 PM ET other material materiality 0.70 positive item 8.01

  Absci completes first milestone in AstraZeneca oncology collaboration; AI-designed antibodies delivered

  Absci delivered AI-designed antibody sequences to AstraZeneca, fulfilling first milestone under December 2023 collaboration.

• August 14, 2024, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 8.01item 9.01

  Absci Q2 2024: revenue $1.3M, net loss $24.8M; ABS-101 half-life 2-3x; MSK collab

  Q2 revenue $1.3M (down from $3.4M YoY); net loss $24.8M vs $41.7M (incl. $21.3M non-cash impairment in prior year).

• May 14, 2024, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01 ◈ Earnings Releases

  Absci reports Q1 net loss $22M, cash $161.5M; advances ABS-101 to IND-enabling studies

  Q1 2024 revenue $0.9M (down from $1.3M YoY); net loss $22.0M vs $23.4M prior year.

• March 21, 2024, 7:59 PM ET earnings materiality 0.70 positive item 2.02item 9.01 ◈ Earnings Releases

  Absci Q4 net loss $23.5M; initiates IND-enabling for ABS-101; AstraZeneca deal up to $247M

  FY23 net loss $110.6M, revenue $5.7M flat YoY; Q4 net loss $23.5M.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.80 · Median 0.70 · Most common event earnings

5 positive 0 negative 16 neutral

source · ABSI on sec.gov